ArticleJournal of translational medicine2025
Identification of prognostic liquid biopsy biomarkers in patients with cutaneous squamous cell carcinoma treated with cemiplimab.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic model for three-year postoperative local recurrence in cutaneous squamous cell carcinoma: a Chinese multicenter cohort study.Frontiers in oncology · 2026Article
- Prediction of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD-1 inhibition directly from histopathology slides using inferred transcriptomics.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe treatment of Cutaneous Squamous Cell Carcinoma (CSCC) has undergone significant changes with the introduction of Immune Checkpoint Inhibitors (ICIs). While promising results have been observed, their efficacy remains limited to a subset of patients. Soluble immune checkpoint molecules, Interferon-gamma (IFN-γ), and cell-free DNA (cfDNA) could serve as potential biomarkers, particularly in ICI-based therapies.
methodsIn this study, we assessed the prognostic role of serum PD-L1, LAG-3, TIM-3, CTLA-4, IFN-γ, and plasma cfDNA in a cohort of 41 advanced (locally-advanced or metastatic) CSCC patients treated with the anti-PD-1 inhibitor cemiplimab.
resultsOur findings indicate that elevated baseline serum levels of IFN-γ are significantly associated with poorer treatment response and shorter Progression-Free Survival (PFS) in patients receiving cemiplimab. Moreover, patients with worse outcomes in terms of response and PFS exhibited a post-treatment decrease in IFN-γ levels. Higher baseline levels of plasma cfDNA and serum CTLA-4 demonstrated a trend toward association with unfavourable clinical outcomes.
conclusionsThese results highlight the potential of baseline and post-treatment IFN-γ levels as significant prognostic indicators for advanced CSCC patients undergoing cemiplimab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.